What food processing has to do with cannabis
Cannabis, whether for medical or recreational use, must be processed to obtain high quality products.
Receive up-to-date information about the company directly via push notification
Whether as a medicine for the seriously ill or as a leisure luxury, cannabis is now being legalized in more and more countries (such as recently in Canada) and is a rapidly growing market. In the USA alone, it is estimated, the cannabis market could grow to about 15 billion US dollars by 2021.
And this is where companies like EnWave come into play. EnWave - http://www.commodity-tv.net/c/search_adv/?v=299137 - is a leading global supplier of vacuum microwave dehydrogenation technology. Using patented Radiant Energy Vacuum ("REV™") technology, EnWave can dewater organic materials. This is not only possible with food, in cooperation with large companies such as Nestlé, Kellogg´s or Bonduelle, but also with medical products, including cannabis.
For example, EnWave was able to conclude an agreement with a cannabis company working on the production of cannabis material in the EU. EnWave earns on licenses and on the sale of dehydration systems.
As for cannabis, the tide has turned. Canada was the first large western country to legalize medical and recreational cannabis in 2018. In the United States, ten states have legalized recreational cannabis and 33 states have legalized medical cannabis. Other states will follow.
RavenQuest BioMed - http://www.commodity-tv.net/c/search_adv/?v=298816 - is a state-licensed company based in Vancouver. This year, the company intends to increase its production capacity by 275 percent. With the Health Canada sales license, RavenQuest BioMed can manage the sale of cannabis. Plants in Markham and Edmonton produce the cannabis, and all production can now be sold under the existing Markham distribution license.
Current company information and press releases from EnWave (https://www.resource-capital.ch/en/companies/enwave-corp/) and RavenQuest BioMed (https://www.resource-capital.ch/en/companies/ravenquest-biomed-inc/).
In accordance with §34 WpHG, I would like to point out that partners, authors and employees can hold shares in the companies mentioned in each case and therefore there is a possible conflict of interest. Only the German version of these messages applies.
Disclaimer: The information provided does not constitute any form of recommendation or advice. We expressly point out the risks involved in securities trading. No liability can be assumed for damages resulting from the use of this blog. I would like to point out that shares and in particular warrant investments are generally associated with risk. The total loss of the invested capital cannot be excluded. All information and sources are carefully researched. However, no guarantee is given for the correctness of all contents. I expressly reserve the right to make a mistake, in particular with regard to figures and exchange rates, despite the utmost care. The information contained herein has been obtained from sources believed to be reliable but does not claim to be accurate or complete. Due to court rulings the contents of linked external sites are also to answer for (so among other things district court Hamburg, in the judgement of 12.05.1998 - 312 O 85/98), as long as no explicit dissociation from these takes place. Despite careful control of the contents, I do not assume any liability for the contents of linked external sites. The respective operators are solely responsible for their content. The disclaimer of Swiss Resource Capital AG also applies: https://www.resource-capital.ch/en/disclaimer/